CYTK
Price
$67.68
Change
-$6.30 (-8.52%)
Updated
Mar 4, 6:59 PM EST
59 days until earnings call
VBIV
Price
$0.59
Change
+$0.01 (+1.72%)
Updated
Mar 1, 6:59 PM EST
Ad is loading...

Analysis and predictions CYTK vs VBIV

Header iconCYTK vs VBIV Comparison
Open Charts CYTK vs VBIVBanner chart's image
Cytokinetics
Price$67.68
Change-$6.30 (-8.52%)
Volume$2.22M
CapitalizationN/A
VBI Vaccines
Price$0.59
Change+$0.01 (+1.72%)
Volume$65.67K
CapitalizationN/A
View a ticker or compare two or three
CYTK vs VBIV Comparison Chart

Loading...

CYTKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VBIVDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CYTK vs. VBIV commentary
Mar 04, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and VBIV is a Hold.

COMPARISON
Comparison
Mar 04, 2024
Stock price -- (CYTK: $73.98 vs. VBIV: $0.59)
Brand notoriety: CYTK and VBIV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 33% vs. VBIV: 52%
Market capitalization -- CYTK: $7.25B vs. VBIV: $13.98M
CYTK [@Biotechnology] is valued at $7.25B. VBIV’s [@Biotechnology] market capitalization is $13.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $550.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 2 FA rating(s) are green whileVBIV’s FA Score has 1 green FA rating(s).

  • CYTK’s FA Score: 2 green, 3 red.
  • VBIV’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTK is a better buy in the long-term than VBIV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 3 TA indicator(s) are bullish while VBIV’s TA Score has 4 bullish TA indicator(s).

  • CYTK’s TA Score: 3 bullish, 5 bearish.
  • VBIV’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both CYTK and VBIV are a bad buy in the short-term.

Price Growth

CYTK (@Biotechnology) experienced а -5.18% price change this week, while VBIV (@Biotechnology) price change was +3.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.19%. For the same industry, the average monthly price growth was +19.18%, and the average quarterly price growth was +53.54%.

Reported Earning Dates

CYTK is expected to report earnings on May 02, 2024.

VBIV is expected to report earnings on Aug 09, 2023.

Industries' Descriptions

@Biotechnology (+4.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CYTK with price predictions.
OPEN
A.I.dvisor published
a Summary for VBIV with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CYTK($7.25B) has a higher market cap than VBIV($14M). VBIV YTD gains are higher at: 0.426 vs. CYTK (-11.391). VBIV has higher annual earnings (EBITDA): -104.08M vs. CYTK (-462.64M). CYTK has more cash in the bank: 539M vs. VBIV (35.5M). VBIV has less debt than CYTK: VBIV (52.7M) vs CYTK (748M). VBIV (8.12M) and CYTK (7.82M) have equivalent revenues.
CYTKVBIVCYTK / VBIV
Capitalization7.25B14M51,814%
EBITDA-462.64M-104.08M445%
Gain YTD-11.3910.426-2,677%
P/E RatioN/AN/A-
Revenue7.82M8.12M96%
Total Cash539M35.5M1,518%
Total Debt748M52.7M1,419%
FUNDAMENTALS RATINGS
CYTK vs VBIV: Fundamental Ratings
CYTK
VBIV
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
12100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
3592
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VBIV's Valuation (16) in the Biotechnology industry is significantly better than the same rating for CYTK (100). This means that VBIV’s stock grew significantly faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (12) in the Biotechnology industry is significantly better than the same rating for VBIV (100). This means that CYTK’s stock grew significantly faster than VBIV’s over the last 12 months.

VBIV's SMR Rating (99) in the Biotechnology industry is in the same range as CYTK (100). This means that VBIV’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for VBIV (92). This means that CYTK’s stock grew somewhat faster than VBIV’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for VBIV (100). This means that CYTK’s stock grew significantly faster than VBIV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKVBIV
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 4 days ago
87%
Declines
ODDS (%)
Bearish Trend 5 days ago
74%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
84%
Aroon
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
80%
View a ticker or compare two or three
Ad is loading...
CYTKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VBIVDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NDIV27.330.34
+1.25%
Amplify Natural Resources Div Inc ETF
ISRA37.880.34
+0.92%
VanEck Israel ETF
DFUV38.980.25
+0.65%
Dimensional US Marketwide Value ETF
BSMO24.800.04
+0.16%
Invesco BulletShares (R) 2024MuncplBdETF
WCLD35.800.04
+0.11%
WisdomTree Cloud Computing ETF

VBIV and

Correlation & Price change

A.I.dvisor indicates that over the last year, VBIV has been loosely correlated with SRNEQ. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if VBIV jumps, then SRNEQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VBIV
1D Price
Change %
VBIV100%
+1.72%
SRNEQ - VBIV
63%
Loosely correlated
-25.93%
MDGL - VBIV
56%
Loosely correlated
+6.53%
AXON - VBIV
48%
Loosely correlated
+2.24%
CYTK - VBIV
44%
Loosely correlated
+2.41%
ORMP - VBIV
42%
Loosely correlated
+3.95%
More